Literature DB >> 16078320

Neuropsychiatric syndromes in patients with systemic lupus erythematosus and rheumatoid arthritis.

John G Hanly1, John D Fisk, Grace McCurdy, Lisa Fougere, Jo-Anne Douglas.   

Abstract

OBJECTIVE: The cause of neurologic (N) and psychiatric (P) syndromes in patients with systemic lupus erythematosus (SLE) is mutifactorial and includes primary immunopathogenic mechanisms, nonspecific sequelae of chronic disease, and concurrent illnesses. We compared the prevalence, diversity, and clinical significance of NP syndromes in patients with SLE and rheumatoid arthritis (RA).
METHODS: Fifty-three patients with SLE were matched by age and sex to 53 patients with RA attending ambulatory clinics in a single academic medical center. All fulfilled the American College of Rheumatology (ACR) classification criteria for either SLE or RA. Cumulative NP manifestations were determined using the ACR nomenclature and case definitions for 19 NP syndromes. Depression and anxiety were measured by the Hospital Anxiety and Depression Scales (HADS) and symptoms of cognitive dysfunction were assessed by the Cognitive Symptoms Inventory (CSI). Health related quality of life (HRQOL) was evaluated by the SF-36 and fatigue by a 10 point Likert scale.
RESULTS: The patients were well matched with regard to age, sex, disease duration, and years of education. There were no significant differences in self-reported HRQOL, fatigue, anxiety, depression, and cognitive symptoms between the 2 groups. The proportion of patients with cumulative NP events was higher in RA than in SLE patients (47% vs 28%; p = 0.045), and of these the occurrence of multiple NP events in individual patients was comparable in both groups (SLE 53%; RA 48%; p = 0.75). Fifty-five percent and 66% of NP events occurred prior to the diagnosis of SLE and RA, respectively. NP events common to both SLE and RA patients were headaches, mood disorders, acute confusional states, anxiety, cerebrovascular disease, and cognitive dysfunction. Seizures and demyelinating syndrome occurred only in SLE patients, but were rare. Depression scores (HADS) were significantly higher in SLE patients with a history of cumulative NP events compared to RA patients with NP events (p = 0.02). Similarly, symptoms of cognitive dysfunction (CSI) were more common in SLE patients with a history of NP manifestations (p = 0.02). However, there were no significant differences in SF-36 subscale or fatigue scores between SLE and RA patients with cumulative NP events.
CONCLUSION: NP syndromes, regardless of etiology, are common in both SLE and RA patients. SLE patients with NP syndromes report more symptoms of depression and cognitive dysfunction compared to RA patients with NP syndromes, but do not report significantly poorer HRQOL. These results emphasize the presence of non-disease-specific causes of NP manifestations in SLE patients, which should be acknowledged in future studies of pathogenesis and treatment.

Entities:  

Mesh:

Year:  2005        PMID: 16078320

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  28 in total

Review 1.  Beyond the joints: neurological involvement in rheumatoid arthritis.

Authors:  Cesar Ramos-Remus; Sergio Duran-Barragan; Jose Dionisio Castillo-Ortiz
Journal:  Clin Rheumatol       Date:  2011-09-20       Impact factor: 2.980

2.  Libman-Sacks endocarditis and embolic cerebrovascular disease.

Authors:  Carlos A Roldan; Wilmer L Sibbitt; Clifford R Qualls; Rex E Jung; Ernest R Greene; Charles M Gasparovic; Reyaad A Hayek; Gerald A Charlton; Kendall Crookston
Journal:  JACC Cardiovasc Imaging       Date:  2013-09

3.  Effectiveness of olanzapine for systemic lupus erythematosus-related psychosis.

Authors:  Joel P Pinto; Silvio Luiz Morais; Jaime E C Hallak; Serdar M Dursun
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

Review 4.  The impact and implications of neuropsychiatric systemic lupus erythematosus in adolescents.

Authors:  Marisa Klein-Gitelman; Hermine I Brunner
Journal:  Curr Rheumatol Rep       Date:  2009-07       Impact factor: 4.592

Review 5.  Healthcare burden of depression in adults with arthritis.

Authors:  Usha Sambamoorthi; Drishti Shah; Xiaohui Zhao
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2017-01-20       Impact factor: 2.217

Review 6.  Anxiety and Mood Disorders in Systemic Lupus Erythematosus: Current Insights and Future Directions.

Authors:  Annaliese Tisseverasinghe; Christine Peschken; Carol Hitchon
Journal:  Curr Rheumatol Rep       Date:  2018-11-12       Impact factor: 4.592

7.  Neurologic manifestations of systemic immunopathological diseases.

Authors:  Marc Gotkine; Adi Vaknin-Dembinsky
Journal:  Curr Treat Options Neurol       Date:  2012-06       Impact factor: 3.598

Review 8.  Neurocognitive impairment in children and adolescents with systemic lupus erythematosus.

Authors:  Deborah M Levy; Stacy P Ardoin; Laura E Schanberg
Journal:  Nat Clin Pract Rheumatol       Date:  2009-02

9.  Transient life-threatening cerebral edema in a patient with systemic lupus erythematosus.

Authors:  Matt T Bianchi; Catherine Lavigne; Farzaneh Sorond; Bonnie Bermas
Journal:  J Clin Rheumatol       Date:  2009-06       Impact factor: 3.517

10.  Differential impact of systemic lupus erythematosus and rheumatoid arthritis on health-related quality of life.

Authors:  Benjamin Chaigne; Axel Finckh; Deshire Alpizar-Rodriguez; Delphine Courvoisier; Camillo Ribi; Carlo Chizzolini
Journal:  Qual Life Res       Date:  2017-03-11       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.